[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/pages/docs/Benef/index.md) >> Individual ID:PBN__Benef_915 

# __Enhanced treatment options__

## Articles mentionning this Benefit

* [Graphene-based nanomaterials as antimicrobial surface coatings: A parallel approach to restrain the expansion of COVID-19](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_187.md)

## Category to which it belongs

* [Improved outcomes, reduced vulnerability, and enhanced efficiency are achieved through a variety of measures and interventions.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_18.md)

## Description of actual returns pertaining to this benefit

* [Private investors can benefit from the increased demand for graphene-based coatings in healthcare settings, leading to potential profit and market growth.](https://github.com/mm80843/T3.5/blob/pages/BenefReturn/PBN__BenefReturn_1007.md)

## Name of the Benefit

Graphene-based coatings can provide an additional layer of protection against virus transmission, complementing existing treatment options and improving patient outcomes.

## Risks which can benefit from this action

* [Development of graphene-based antiviral coatings](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_918.md)

## Stakeholders benefitting from this Benefit

* [Healthcare facilities](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_31.md)
* [Patients](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_33.md)

